Location: Geneva, Switzerland
Working time: 100%
Contract: Three-year contract
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase equitable access to innovative medicines (small molecules and biologics) and other health technologies through public health-oriented voluntary licensing and technology transfer. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19, a COVID-19 serological antibody diagnostic test and a drug for cancer treatment.
In addition, MPP is co-leading the mRNA technology transfer Hub programme together with WHO. This programme is a global initiative that aims to contribute towards enabling equitable access to mRNA vaccines by: increasing the distribution of sustainable manufacturing capacity across countries to respond to epidemics and supporting future pandemic readiness; enhancing regional and inter-regional collaborations; and developing and empowering local workforce through tailored and inclusive trainings and expert support. To achieve this objective, MPP and WHO are supporting the development of a mRNA technology platform and applying it to manufacture mRNA vaccine(s) at an industrial scale adhering to Good Manufacturing Practices (GMP). Subsequently, the mRNA technology transfer hub will transfer the know-how, along with a comprehensive technical package and appropriate training to 15 manufacturers (spokes) in LMICs. Initially, the hub will support the global efforts to respond to the COVID-19 pandemic by transferring an mRNA-based COVID-19 vaccine to the spokes. The hub will also explore improvements to the mRNA vaccine technology and its application to other disease targets. The transfer of the latest know-how and technological advances aims to contribute to the inter-pandemic sustainability of the manufacturers in LMICs. For more information, please see our website, https://medicinespatentpool.org/
To achieve the objectives set forth above, MPP has created a Technology Transfer workstream whose mission is to: facilitate the technology transfer to LMICs manufacturers for products whose licenses have been acquired by MPP; contribute to the mRNA Programme activities by supporting product development, coordinating and supporting technology transfer, monitoring budgets, raising and managing funds raised by MPP for the Programme, reporting to the funders, and cross-coordinating activities between MPP and the other stakeholders.
Reporting to the Technology Transfer Programme Manager, the Project Manager will play a key role in ensuring the success of MPP in these new areas of intervention.
The main activities of the Technology Transfer Project Manager will be to support MPP and specifically the technology transfer team by:
MPP’s richness lies in its staff: a small dynamic and multicultural team!
To flourish in our team, you must recognise yourself in our values: Respect, Courage, Generosity and Commitment.
Moreover, the Project Manager Technology Transfer will need to demonstrate the following qualities:
MPP respects all individuals regardless of race, gender, ethnicity, sexual orientation, religion, HIV status or disability. All qualified applications are welcome.
If you recognise yourself in this description and wish to join our outstanding team, please send a cover letter and C.V. to recruitment@medicinespatentpool.org including “Project Manager_MPP” as reference in the subject line by 24 February 2023
Département communication, presse et médias
Le Medicines Patent Pool (MPP) est une organisation de santé publique soutenue par les Nations Unies, dont la mission est d’améliorer l’accès à des médicaments essentiels dans les pays à revenu faible et intermédiaire, et de faciliter la mise au point de tels médicaments. Au travers de son modèle économique innovant, le MPP collabore avec la société civile, les gouvernements, des organisations internationales, l’industrie, des groupes de patients et d’autres acteurs afin d’établir des priorités, de délivrer des licences sur les médicaments indispensables et de centraliser les actifs de propriété intellectuelle pour faciliter la fabrication de médicaments génériques et l’élaboration de nouvelles formulations.
À ce jour, le MPP a signé des accords avec 22 titulaires de brevets pour 13 antirétroviraux contre le VIH, une plateforme technologique sur le VIH, trois antiviraux à action directe contre l’hépatite C, un traitement contre la tuberculose, un traitement contre le cancer, quatre technologies à action prolongée, un traitement de l’hémorragie du post-partum, trois traitements antiviraux oraux contre la COVID-19 et 16 technologies liées à la COVID-19.
MPP a été fondé par Unitaid, qui continue d’être le principal bailleur de fonds de MPP. Le travail de MPP sur l’accès aux médicaments essentiels est également financé par l’Agence suisse pour le développement et la coopération (SDC), le gouvernement du Canada, l’Organisation mondiale de la propriété intellectuelle (OMPI) et le gouvernement de la Flandre. Les activités de MPP dans le cadre de la COVID-19 sont entreprises avec le soutien financier du gouvernement japonais, du ministère français de l’Europe et des Affaires étrangères, de l’Agence allemande de coopération internationale et de la SDC.